Yes, a significant cost AND it would not only need to address the solubility issue which held back RC110, but also need to notably outperform RC220 to be viable for trials and commercilisation.
Could Bisantrene be tweaked further? Perhaps. Race Oncology is already doing this in the background, namely for potential FTO opportunities.
Yes, a significant cost AND it would not only need to address...
-
- There are more pages in this discussion • 186 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.050(3.33%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.55 | $1.49 | $86.32K | 57.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4520 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 2259 | 1 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |